Cancer Care

Uses

How it works

Risks & contraindications

Background

Highlighted claims

• Around 393,000 people are diagnosed with cancer annually in the UK, and approximately 3 million were living with cancer in 2020, a number expected to rise to 4 million by 2030. — What are the views of cancer care administrators and clinicians in England on the use of a machine learning clinical decision support system (ML-CDSS) to predict patients’ risk of hepatic and renal deterioration during chemotherapy? A qualitative study
• Pressures on UK cancer services from an ageing population, workforce shortages, socioeconomic inequalities, resource constraints, and COVID-19 contribute to long diagnostic and treatment waiting times. — What are the views of cancer care administrators and clinicians in England on the use of a machine learning clinical decision support system (ML-CDSS) to predict patients’ risk of hepatic and renal deterioration during chemotherapy? A qualitative study
• All NHS and non-NHS cancer providers in England operate a team-based model with defined responsibilities across specialist doctors, pharmacists, and nurses. — What are the views of cancer care administrators and clinicians in England on the use of a machine learning clinical decision support system (ML-CDSS) to predict patients’ risk of hepatic and renal deterioration during chemotherapy? A qualitative study
• AI and machine learning are increasingly being explored to improve the efficiency, safety, and personalisation of cancer care, including through predictive analytics supporting precision oncology. — What are the views of cancer care administrators and clinicians in England on the use of a machine learning clinical decision support system (ML-CDSS) to predict patients’ risk of hepatic and renal deterioration during chemotherapy? A qualitative study